Intestinal Perforation Secondary to Bortezomib-Induced Autonomic Neuropathy.
Jose Antonio Sánchez Salas, Maria Jose Moreno Belmonte, Andrea Poveda García, Estela Ruiz Ruiz, Eva Soler Espejo, Valentin Cabanas Perianes, Ana María García Hernandez
Author Information
Jose Antonio Sánchez Salas: Department of Hematology Virgen de la Arrixaca University Hospital Murcia Spain. ORCID
Maria Jose Moreno Belmonte: Department of Hematology Virgen de la Arrixaca University Hospital Murcia Spain.
Andrea Poveda García: Department of Hematology Virgen de la Arrixaca University Hospital Murcia Spain.
Estela Ruiz Ruiz: Department of Hematology Virgen de la Arrixaca University Hospital Murcia Spain.
Eva Soler Espejo: Department of Hematology Virgen de la Arrixaca University Hospital Murcia Spain.
Valentin Cabanas Perianes: Department of Hematology Virgen de la Arrixaca University Hospital Murcia Spain. ORCID
Ana María García Hernandez: Department of Hematology Virgen de la Arrixaca University Hospital Murcia Spain.
It is essential to evaluate both the patient's prior conditions and the severity of the current clinical presentation when deciding on BTZ toxicity management. It seems prudent to consider the permanent discontinuation of the drug in patients who have experienced at least grade 3 intestinal neuropathy and have structural abnormalities or other risk factors for intestinal perforation. NCT03710603.
